Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis

Endocrinology

Volumn 140, Issue 10, 1999, Pages 4382-4389

  Hofbauer, L C ^a   Gori, F ^a   Riggs, B L ^a   Lacey, D L ^a   Dunstan, C R ^a   Spelsberg, T C ^a   Khosla, S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; CYCLOHEXIMIDE; DEXAMETHASONE; GLUCOCORTICOID; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL CELL; ARTICLE; DOSE TIME EFFECT RELATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; NORTHERN BLOTTING; OSTEOBLAST; OSTEOPOROSIS; PARACRINE SIGNALING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE;

EID: 0033304809     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.10.7034     Document Type: Article

References (46)

1. Glucocorticoid-induced osteoporosis: Pathogenesis and management
2. Glucocorticoid osteoporosis - Mechanisms and management
3. Mechanisms of glucocorticoid action in bone cells
4. Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone
5. 2
6. Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro
7. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: Study in eumenorrheic patients with Cushing's syndrome
8. Quantitative microradiographic study of bone remodeling in Cushing's syndrome
9. Bone histomorphometry in glucocorticoid-induced osteoporosis
10. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanism of their deleterious effects on bone
11. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis
12. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
13. Identiy of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
14. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
15. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells
16. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption
17. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
18. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
19. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
20. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
21. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells
22. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
23. OPGL is a key regulator of osteodastogenesis, lymphocyte development and lymph-node organogenesis
24. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
25. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
26. Estrogen stimulates production of the antiresorptive cytokine receptor osteoprotegerin in human osteoblastic cells
27. Tumor necrosis factor-α and β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells
28. Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells
29. 2 in human bone marrow stroma cells
30. Development and characterization of conditionally immortalized osteoblast precursor cell lines from human bone marrow stroma
31. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line
32. Human bone cells in vitro
33. Cytokine production in the bone marrow microenvironment: Failure to demonstrate estrogen regulation in early postmenopausal women
34. RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination
35. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose
36. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity
37. Bone morphogenetic protein-6 production in human osteoblastic cells: Selective regulation by estrogen
38. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei
39. Cortisol stimulation of parathyroid hormone secretion by rat parathyroid glands in organ culture
40. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
41. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis
42. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
43. Biologic basis for interleukin-1 in disease
44. The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line
45. Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies
46. Modulation of tumor necrosis factor (TNF) receptor expression during monocytic differentiation